The crystal engineering of salbutamol sulphate via simulated pulmonary surfactant monolayers.

International journal of pharmaceutics (2013-02-09)
Michael J Davies, Thomas D Kerry, Linda Seton, Mark F Murphy, Paul Gibbons, Jiyi Khoo, Majid Naderi
RESUMEN

This study aims to crystallise salbutamol sulphate beneath simulated pulmonary surfactant monolayers. Such ensembles serve as heterogeneous nucleating sites to direct crystallisation. This contribution builds upon previous work to confirm the suitability of Langmuir monolayers in supporting the rational generation of respirable therapeutic material. Langmuir monolayers (i.e. DPPC or a 'mixed' system) were supported on a subphase containing the extremely water soluble model drug (2.5 g/ml) and compressed to 5 mN m(-1) or 35 mN m(-1) whilst experiencing a temperature reduction and positioned within a humid environment. Control samples were produced via batch crystallisation. Analysis involved scanning electron microscopy (SEM), atomic force microscopy (AFM), powder X-ray diffraction (PXRD) and inverse gas chromatography (IGC). Expanded Langmuir isotherms confirmed drug-surfactant interaction; crystal growth was inhibited at high surface pressure. Resultant crystals exhibited a range of morphologies, dependent upon the crystallisation route. AFM analysis highlighted nanoscale surface undulations. IGC data confirmed sample surface energy profiles were variable and influenced by crystallisation route. Principal modes of drug-surfactant interaction are proposed as hydrogen bond and ion-dipole associations. A range of pharmaceutical approaches have been applied to understand drug-surfactant complementarity. The results strengthen the argument for the use of Langmuir monolayers in drug particle engineering.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Palmitic acid, ≥99%
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Supelco
Palmitic acid, analytical standard
Supelco
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Salbutamol
Sigma-Aldrich
Palmitic acid, ≥95%, FCC, FG
Supelco
Albuterol sulfate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Palmitic acid, natural, 98%, FG
Sigma-Aldrich
Palmitic acid, ≥98% palmitic acid basis (GC)
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
Salbutamol sulfate, European Pharmacopoeia (EP) Reference Standard
Supelco
Salbutamol, VETRANAL®, analytical standard
Sigma-Aldrich
1,2-Dipalmitoyl-rac-glycero-3-phosphocholine, ~99%
Sigma-Aldrich
Salbutamol hemisulfate salt, ≥98%
Supelco
Palmitic acid, certified reference material, TraceCERT®
Supelco
Salbutamol hemisulfate salt, VETRANAL®, analytical standard